Gastroenterología y Hepatología (English Edition)最新文献

{"title":"Cerebral thrombosis as a manifestation of poor control in inflammatory bowel disease","authors":"Marta Fernández Carrasco, Ana Delgado Maroto, Álvaro Hernández Martínez","doi":"10.1016/j.gastre.2024.502256","DOIUrl":"10.1016/j.gastre.2024.502256","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502256"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143140420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptation and validation of an abbreviated version of the SIPAT integrated psychosocial risk scale in patients with liver cirrhosis candidates for liver transplantation (SIPAT-11)","authors":"Natalia García Morales ,&nbsp;Sagrario Gutiérrez Morato ,&nbsp;Carmen Castillo Cejas ,&nbsp;Margarita Fernández de la Varga ,&nbsp;Martín Menéndez Rodríguez ,&nbsp;Victoria Aguilera ,&nbsp;Salvador Benlloch ,&nbsp;Luis Menéndez Rodríguez ,&nbsp;Teresa Seoane Pillado ,&nbsp;Joaquín Cubiella","doi":"10.1016/j.gastre.2024.502220","DOIUrl":"10.1016/j.gastre.2024.502220","url":null,"abstract":"<div><h3>Introduction</h3><div>Patients with liver cirrhosis who are candidates for liver transplantation must be evaluated both clinically and socially in order to obtain the optimal outcomes and avoid futile therapeutic measures. For the evaluation of the social aspects in these patients, no validated scale in Spanish is available. The SIPAT (Stanford Integrated Psychosocial Assessment for Transplantation) scale is an instrument that measures the social, family and psychological aspects in candidates for solid organ transplantation. The objective of this study is to adapt and validate an abbreviated version of the SIPAT scale in Spanish for patients with liver cirrhosis.</div></div><div><h3>Material and methods</h3><div>Prospective observational study carried out in the Hepatology Unit of the La Fe Unversity Hospital in Valencia, by questionnaire validation methodology. To analyze the reliability of the questionnaire, the internal consistency of all variables was calculated, for variability an exploratory factor analysis, and for stability the test-retest test was carried out.</div></div><div><h3>Results</h3><div>96 patients who were admitted for decompensated cirrhosis to the Hepatology Unit of the La Fe Hospital in Valencia between November 1, 2017 and January 31, 2017 were selected. 84% were men, the mean age was 60.01 (SD 10.12) years. In 73.2% of those admitted, the etiology of cirrhosis was alcoholic. 14.4% had a Child's stage A, 57.7% B and 27.8% C. The internal consistency of all variables reached a Cronbach's Alpha of 0.766. In the exploratory factor analysis, 6 dimensions of the questionnaire were identified that explain 84.27% of the total variability. To see the stability of the instrument, the measurement was repeated at 2 and 6 months of follow-up, obtaining in the test-retest a kappa agreement of 0.612 and 0.565 respectively.</div></div><div><h3>Conclusion</h3><div>The SIPAT-11 questionnaire has good psychometric characteristics in cirrhotic patients who are candidates for liver transplantation. It is easy to complete and can be administered by professionals who are not specialists in the area of ​​Mental Health.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"48 1","pages":"Article 502220"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143139831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years","authors":"Rafael Esteban ,&nbsp;Raquel Domínguez-Hernández ,&nbsp;Helena Cantero ,&nbsp;Miguel Ángel Casado","doi":"10.1016/j.gastre.2024.502199","DOIUrl":"10.1016/j.gastre.2024.502199","url":null,"abstract":"<div><h3>Objective</h3><div>Direct-acting antivirals for the treatment of hepatitis C virus (HCV) represented a paradigm shift. In 2017, sofosbuvir/velpatasvir (SOF/VEL-Epclusa®) was approved, which showed a high cure rate in all patient, contributing to HCV elimination. The analysis aimed to quantify the clinical and economic value of SOF/VEL in HCV chronic patients since its approval in Spain.</div></div><div><h3>Methods</h3><div>An economic evaluation was elaborated adapting a Markov model that simulated the lifetime disease progression in of all HCV chronic patients treated with SOF/VEL (30,488 patients) since its launch (5-years), compared to previous therapies. Patients entered the model and were distributed between the fibrosis states (F0-to-F4) in treated and untreated. All patients (100%) were treated with SOF/VEL regardless of their fibrosis, and 49% with previous therapies in ≥F2. The average sustained viral response (SVR) rates 98.9% SOF/VEL versus 61.0% previous therapies. All parameters for the analysis were obtained from real-life data and literature. Only direct healthcare costs associated with disease management were included. The SOF/VEL value was measured as the number of hepatic complications avoided and their associated cost, and hepatic mortality compared to previous therapies. National Health System perspective and a 3% discount rate was applied.</div></div><div><h3>Results</h3><div>SOF/VEL decreased the number of liver complications, avoiding 92% decompensated cirrhosis, 80% hepatocellular carcinomas, and 87% liver transplants, as well as 85% liver-related mortality. Their cost associated was reduced, amounting to savings of 197<!--> <!-->M€.</div></div><div><h3>Conclusion</h3><div>SOF/VEL adds relevant value to the HCV treatment, reducing the clinical and economic disease burden and contributing to HCV elimination in Spain.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502199"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol-related liver disease: (Re)compensation of abstinence","authors":"Joaquín Cabezas ,&nbsp;José Ignacio Fortea ,&nbsp;Ángela Puente Sánchez ,&nbsp;Rocío Gallego-Durán ,&nbsp;Andrés Conthe ,&nbsp;David Martí-Aguado","doi":"10.1016/j.gastre.2024.502263","DOIUrl":"10.1016/j.gastre.2024.502263","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502263"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142719604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)","authors":"Edilmar Alvarado-Tapias ,&nbsp;Douglas Maya-Miles ,&nbsp;Agustin Albillos ,&nbsp;Rocio Aller ,&nbsp;Javier Ampuero ,&nbsp;Raul J. Andrade ,&nbsp;Maria Arechederra ,&nbsp;Patricia Aspichueta ,&nbsp;Jesus M. Banales ,&nbsp;Ana Blas-García ,&nbsp;Esther Caparros ,&nbsp;Teresa Cardoso Delgado ,&nbsp;Antonio Carrillo-Vico ,&nbsp;Joan Claria ,&nbsp;Francisco Javier Cubero ,&nbsp;Alberto Díaz-Ruiz ,&nbsp;Maite G. Fernández-Barrena ,&nbsp;Anabel Fernández-Iglesias ,&nbsp;Sonia Fernández-Veledo ,&nbsp;Ruben Francés ,&nbsp;Manuel D. Gahete","doi":"10.1016/j.gastre.2024.502207","DOIUrl":"10.1016/j.gastre.2024.502207","url":null,"abstract":"<div><div>This is the summary report of the 5th Translational Hepatology Meeting, endorsed by the Spanish Association for the Study of the Liver (AEEH) and held in Seville, Spain, in October 2023. The meeting aimed to provide an update on the latest advances in the field of basic and translational hepatology, covering different molecular, cellular, and pathophysiological aspects of the most relevant clinical challenges in liver pathologies. This includes the identification of novel biomarkers and diagnostic tools, the understanding of the relevance of immune response and inflammation in liver diseases, the characterization of current medical approaches to reverse liver diseases, the incorporation of novel molecular insights through omics techniques, or the characterization of the impact of toxic and metabolic insults, as well as other organ crosstalk, in liver pathophysiology.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502207"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142719605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of obstructive defecation from a structural and a functional perspective","authors":"Lluís Mundet ,&nbsp;Alba Raventós ,&nbsp;Sílvia Carrión ,&nbsp;Cristina Bascompte ,&nbsp;Pere Clavé","doi":"10.1016/j.gastre.2024.502219","DOIUrl":"10.1016/j.gastre.2024.502219","url":null,"abstract":"<div><h3>Background/aims</h3><div>Defecation disorders can occur as a consequence of functional or structural anorectal dysfunctions during voiding. The aims of this study is to assess the prevalence of structural (SDD) vs functional (FDD) defecation disorders among patients with clinical complaints of obstructive defecation (OD) and their relationship with patients’ expulsive capacity.</div></div><div><h3>Patients and methods</h3><div>Retrospective study of 588 patients with OD studied between 2012 and 2020 with evacuation defecography (ED), and anorectal manometry (ARM) in a subgroup of 294.</div></div><div><h3>Results</h3><div>90.3% patients were women, age was 58.5<!--> <!-->±<!--> <!-->12.4 years. Most (83.7%) had SDD (43.7% rectocele, 45.3% prolapse, 19.3% enterocele, and 8.5% megarectum), all SDD being more prevalent in women except for megarectum. Functional assessments showed: (a) absence of rectification of anorectal angle in 51% of patients and poor pelvic descent in 31.6% at ED and (b) dyssynergic defecation in 89.9%, hypertonic IAS in 44%, and 33.3% rectal hyposensitivity, at ARM. Overall, 46.4% of patients were categorized as pure SDD, 37.3% a combination of SDD<!--> <!-->+<!--> <!-->FDD, and 16.3% as having pure FDD.</div><div>Rectal emptying was impaired in 66.2% of SDD, 71.3% of FDD and in 78% of patients with both (<em>p</em> <!-->=<!--> <!-->0.017).</div></div><div><h3>Conclusions</h3><div>There was a high prevalence of SDD in middle-aged women with complaints of OD. Incomplete rectal emptying was more prevalent in FDD than in SDD although FDD and SDD frequently coexist. We recommend a stepwise therapeutic approach always starting with therapy directed to improve FDD and relaxation of striated pelvic floor muscles.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502219"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bile acid malabsorption diarrhea as a clinical manifestation of terminal ileum endometriosis","authors":"Claudia Herrera-deGuise ,&nbsp;Marina Planes-Conangla ,&nbsp;Miquel Kraft Carré ,&nbsp;Miquel Masachs","doi":"10.1016/j.gastre.2024.502206","DOIUrl":"10.1016/j.gastre.2024.502206","url":null,"abstract":"","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502206"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The endoscopic model for gastric carcinogenesis and Helicobacter pylori infection: A potential visual mind-map during gastroscopy examination","authors":"Pedro Delgado-Guillena ,&nbsp;Mireya Jimeno ,&nbsp;Antonio López-Nuñez ,&nbsp;Henry Córdova ,&nbsp;Gloria Fernández-Esparrach","doi":"10.1016/j.gastre.2024.502214","DOIUrl":"10.1016/j.gastre.2024.502214","url":null,"abstract":"<div><div><em>Helicobacter pylori</em> (<em>Hp</em>) is the main trigger of chronic gastric atrophy and the main leading cause of gastric cancer. <em>Hp</em> infects the normal gastric mucosa and can lead to chronic inflammation, glandular atrophy, intestinal metaplasia, dysplasia and finally adenocarcinoma. Chronic inflammation and gastric atrophy associated with Hp infection appear initially in the distal part of the stomach (the antrum) before progressing to the proximal part (the corpus–fundus). In recent years, endoscopic developments have allowed for the characterization of various gastric conditions including the normal mucosa (pyloric/fundic gland pattern and regular arrangement of collecting venules), Hp-related gastritis (Kyoto classification), glandular atrophy (Kimura–Takemoto classification), intestinal metaplasia (Endoscopic Grading of Gastric Intestinal Metaplasia), and dysplasia/adenocarcinoma (Vessel plus Surface classification). Despite being independent classifications, all these scales can be integrated into a single model: the endoscopic model for gastric carcinogenesis. This model would assist endoscopists in comprehending the process of gastric carcinogenesis and conducting a systematic examination during gastroscopy. Having this model in mind would enable endoscopists to promptly recognize the implications of <em>Hp</em> infection and the potential patient's risk of developing gastric cancer.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502214"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of granulocyte–monocyte apheresis and ustekinumab: Multicentre and retrospective study","authors":"Iago Rodríguez-Lago ,&nbsp;Claudia Herrera-deGuise ,&nbsp;Maia Boscá-Watts ,&nbsp;Cristina Rodríguez ,&nbsp;Eduardo Leo-Carnerero ,&nbsp;María Calvo Íñiguez ,&nbsp;Fiorella Cañete ,&nbsp;Silvia Chacón ,&nbsp;Camila Cuarán ,&nbsp;Ainara Elorza ,&nbsp;Elena Guerra-del-Río ,&nbsp;Eva Iglesias ,&nbsp;Damián Sánchez ,&nbsp;Manuel Barreiro-de Acosta ,&nbsp;Daniel Ginard ,&nbsp;José Luis Cabriada","doi":"10.1016/j.gastre.2024.502195","DOIUrl":"10.1016/j.gastre.2024.502195","url":null,"abstract":"<div><h3>Objective</h3><div>Granulocyte–monocyte apheresis (GMA) has shown to be safe and effective in ulcerative colitis (UC), also in combination with biologics, mainly with anti-TNF. The aim of this study was to evaluate the efficacy and safety of combining GMA after primary non-response (PNR) or loss of response (LOR) to ustekinumab (UST) in patients with UC.</div></div><div><h3>Patients and methods</h3><div>A retrospective study was performed in 12 IBD Units, including all patients with refractory UC or unclassified IBD (IBD-U) who received combined GMA plus UST. The number and frequency of GMA sessions, filtered blood volume and time of each session were registered. Efficacy was assessed 1 and 6 months after finishing GMA by partial Mayo score, C-reactive protein (CRP) and fecal calprotectin (FC). Descriptive statistics and non-parametric tests were used in the statistical analysis.</div></div><div><h3>Results</h3><div>Seventeen patients were included (15 UC, 2 IBD-U; median age 47 years [IQR, 35–61]; 59% male; 53% E3). Most patients (89%) had prior exposure to anti-TNF agents and 53% to vedolizumab; 65% were also receiving steroids at baseline. Median partial Mayo score at baseline was 6 (IQR, 5–7) and it significantly decreased after 1 and 6 months (<em>p</em> <!-->=<!--> <!-->0.042 and 0.007, respectively). Baseline FC significantly decreased after 6 months (<em>p</em> <!-->=<!--> <!-->0.028) while no differences were found in CRP. During follow-up, 18% patients started a new biologic therapy and 12% required surgery; 64% of patients under steroids were able to discontinue them. Adverse events were reported in one patient.</div></div><div><h3>Conclusion</h3><div>GMA can recapture the response to UST in selected cases of UC after PNR or LOR to this drug.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502195"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort","authors":"Cristina Suárez Ferrer ,&nbsp;Francisco Mesonero Gismero ,&nbsp;Berta Caballol ,&nbsp;Maria Pilar Ballester ,&nbsp;Iria Bastón Rey ,&nbsp;Andrés Castaño García ,&nbsp;Jose Miranda Bautista ,&nbsp;Rosa Saiz Chumillas ,&nbsp;Jose Manuel Benitez ,&nbsp;Laura Sanchez-Delgado ,&nbsp;Alicia López-García ,&nbsp;Cristina Rubin de Celix ,&nbsp;Inmaculada Alonso Abreu ,&nbsp;Luigi Melcarne ,&nbsp;Rocío Plaza Santos ,&nbsp;Miquel Marques-Camí ,&nbsp;Antonio Caballero Mateos ,&nbsp;César Gómez Díez ,&nbsp;Margalida Calafat ,&nbsp;Horacio Alonso Galan ,&nbsp;Manuel Barreiro-De Acosta","doi":"10.1016/j.gastre.2024.502197","DOIUrl":"10.1016/j.gastre.2024.502197","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Biological therapies used for the treatment of inflammatory bowel disease (IBD) have shown to be effective and safe, although these results were obtained from studies involving mostly a young population, who are generally included in clinical trials. The aim of our study was to determine the efficacy and safety of the different biological treatments in the elderly population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Multicenter study was carried out in the GETECCU group. Patients diagnosed with IBD and aged over 65 years at the time of initiating biological therapy (infliximab, adalimumab, golimumab, ustekinumab or vedolizumab) were retrospectively included.&lt;/div&gt;&lt;div&gt;Among the patients included, clinical response was assessed after drug induction (12 weeks of treatment) and at 52 weeks. Patients’ colonoscopy data in week 52 were assessment, where available. Regarding complications, development of oncological events during follow-up and infectious processes occurring during biological treatment were collected (excluding bowel infection by cytomegalovirus).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 1090 patients were included. After induction, at approximately 12–14 weeks of treatment, 419 patients (39.6%) were in clinical remission, 502 patients (47.4%) had responded without remission and 137 patients (12.9%) had no response.&lt;/div&gt;&lt;div&gt;At 52 weeks of treatment 442 patients (57.1%) had achieved clinical remission, 249 patients had responded without remission (32.2%) and 53 patients had no response to the treatment (6.8%). Before 52 weeks, 129 patients (14.8%) had discontinued treatment due to inefficacy, this being significantly higher (&lt;em&gt;p&lt;/em&gt; &lt;!--&gt;&lt;&lt;!--&gt; &lt;!--&gt;0.0001) for Golimumab – 9 patients (37.5%) – compared to the other biological treatments analyzed.&lt;/div&gt;&lt;div&gt;With respect to tumor development, an oncological event was observed in 74 patients (6.9%): 30 patients (8%) on infliximab, 23 (7.14%) on adalimumab, 3 (11.1%) on golimumab, 10 (6.4%) on ustekinumab, and 8 (3.8%) on vedolizumab. The incidence was significantly lower (&lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.04) for the vedolizumab group compared to other treatments.&lt;/div&gt;&lt;div&gt;As regards infections, these occurred in 160 patients during treatment (14.9%), with no differences between the different biologicals used (&lt;em&gt;p&lt;/em&gt; &lt;!--&gt;=&lt;!--&gt; &lt;!--&gt;0.61): 61 patients (19.4%) on infliximab, 39 (12.5%) on adalimumab, 5 (17.8%) on golimumab, 22 (14.1%) on ustekinumab, and 34 (16.5%) on vedolizumab.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Biological drug therapies have response rates in elderly patients similar to those described in the general population, Golimumab was the drug that was discontinued most frequently due to inefficacy.&lt;/div&gt;&lt;div&gt;In our experience, tumor development was more frequent in patients who used anti-TNF therapies compared to other targets, although its incidence was generally low and that this is in line with younger patients based on previou","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 10","pages":"Article 502197"},"PeriodicalIF":0.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}